Related Experiment Video
Updated: Jul 12, 2026

An Orthotopic Bladder Cancer Model for Gene Delivery Studies
Published on: December 1, 2013
Potential bladder cancer therapeutic delivery systems: a recent update
Oluwadamilola M Kolawole1, Vitaliy V Khutoryanskiy2
1Department of Pharmaceutics and Pharmaceutical Technology, University of Lagos, Lagos, Nigeria.
Introduction:
Bladder Cancer is one of the most expensive cancers to treat due to its high cost of therapy as well as the surveillance expenses incurred to prevent disease recurrence and progression. Thus, there is a strong need to develop safe, efficacious drug formulations with controlled drug release profiles and tumor-targeting potential, for improved therapeutic outcomes of bladder cancer patients.
Areas Covered:
This review aims to provide an overview of drug formulations that have been studied for potential bladder cancer treatment in the last decade; highlight recent trends in bladder cancer treatment; mention ongoing clinical trials on bladder cancer chemotherapy; detail recently FDA-approved drug products for bladder cancer treatment and identify constraints that have prevented the translation of promising drug formulations from the research laboratory to the clinics.
Expert Opinion:
This work revealed that surface functionalization of particulate drug delivery systems and incorporating the nanoparticles into in situ gelling systems could facilitate controlled drug release for extended periods, and improve the prognosis of bladder cancer treatment. Future research directions could incorporate multiple drugs into the drug delivery systems to treat advanced stages of the disease. In addition, smart nanomaterials, including photothermal therapies, could be exploited to improve the therapeutic outcomes of bladder cancer patients.
Insights
Developing advanced drug delivery systems, like functionalized nanoparticles in gelling systems, offers improved bladder cancer treatment with controlled release and tumor targeting. Future research may involve combination therapies and smart nanomaterials for better patient outcomes.
Area of Science:
- Oncology
- Nanotechnology
- Drug Delivery Systems
Background:
- Bladder cancer treatment is costly due to therapy and surveillance needs.
- There's a critical demand for effective, targeted drug formulations to improve patient prognosis.
- Current treatments face challenges in drug release control and tumor specificity.
Purpose of the Study:
- To review drug formulations for bladder cancer treatment over the past decade.
- To highlight recent advancements, clinical trials, and FDA-approved drugs.
- To identify barriers hindering the clinical translation of promising drug delivery systems.
Main Methods:
- Review of scientific literature on bladder cancer drug formulations.
- Analysis of recent trends in bladder cancer treatment strategies.
- Examination of clinical trial data and regulatory approvals.
Main Results:
- Surface-functionalized nanoparticles in in situ gelling systems enhance controlled drug release.
- These advanced systems show potential for improved bladder cancer treatment prognosis.
- Challenges remain in translating laboratory research into clinical applications.
Conclusions:
- Particulate drug delivery systems with surface functionalization and in situ gelling show promise for bladder cancer.
- Future directions include multi-drug systems and smart nanomaterials like photothermal therapies.
- Overcoming translational barriers is key to improving therapeutic outcomes for bladder cancer patients.
More Related Videos
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Tumor Immunotherapy
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Modified-Release Drug Delivery Systems: Site-Targeted
Site-Targeted Drug Delivery Systems: Polymeric Carriers
Intrauterine Drug Delivery Systems

